Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment
- Abstract
- Background: Up to 60% of patients with ulcerative colitis (UC) ultimately fail anti-tumor necrosis factor (TNF) treatment. We aimed to investigate early predictive markers of clinical and endoscopic outcomes in patients with UC who were anti-TNF-naive commencing anti-TNF treatment, with particular focus on changes in albumin and C-reactive protein levels in the first 2 weeks of treatment.
Methods: We retrospectively investigated 210 patients with UC who started infliximab or adalimumab between 2009 and 2016 (male, 62.4%; median age at diagnosis, 37.9 years [interquartile range, 25.5-48.9 years]; median follow-up duration, 3.3 years [1.9-5.0 years]). Logistic and Cox proportional-hazards regressions were performed to identify variables associated with primary nonresponse (PNR), endoscopic outcomes, time-to-colectomy, and anti-TNF failure.
Results: Forty-one patients (19.5%) experienced PNR; week 0/week 2 ratio serum albumin was associated with PNR (adjusted odds ratio [aOR], 1.8; 95% confidence interval [CI], 1.1 2.9, per interquartile range increase). Week 0/week 2 ratio albumin was also associated with endoscopic response (aOR, 0.28; 95% CI, 0.31-0.82) and endoscopic remission (aOR, 0.61; 95% CI, 0.39-0.96) at weeks 8 to 14, time-to-colectomy (adjusted hazard ratio, 2.12; 95% CI, 1.29-3.49) and time-to-anti-TNF failure (adjusted hazard ratio, 1.54; 95% CI, 1.22-1.96), regardless of age, disease severity, or in-patient status. Association with time-to-colectomy and anti-TNF failure was externally validated in an independent cohort of inpatients with UC starting infliximab.
Conclusions: Change in serum albumin within the first 2 weeks of anti-TNF treatment is predictive of PNR, endoscopic outcomes, time-tocolectomy, and anti-TNF failure in patients with UC. Timely access to this biomarker enables early identification of patients with UC at risk of anti-TNF failure and may guide early optimization of anti-TNF treatment to improve disease outcomes.
- Author(s)
- 이선호; Margaret Walshe; 오은혜; 황성욱; 박상형; 양동훈; 변정식; 명승재; 양석균; Tomer Greener; Adam V. Weizman; Mark S. Silverberg; 예병덕
- Issued Date
- 2021
- Type
- Article
- Keyword
- anti-TNF; serum albumin; ulcerative colitis
- DOI
- 10.1093/ibd/izaa309
- URI
- https://oak.ulsan.ac.kr/handle/2021.oak/7194
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_proquest_miscellaneous_2466773438&context=PC&vid=ULSAN&lang=ko_KR&search_scope=default_scope&adaptor=primo_central_multiple_fe&tab=default_tab&query=any,contains,Early%20Changes%20in%20Serum%20Albumin%20Predict%20Clinical%20and%20Endoscopic%20Outcomes%20in%20Patients%20With%20Ulcerative%20Colitis%20Starting%20Anti-TNF%20Treatment&offset=0&pcAvailability=true
- Publisher
- INFLAMMATORY BOWEL DISEASES
- Location
- 미국
- Language
- 영어
- ISSN
- 1078-0998
- Citation Volume
- 27
- Citation Number
- 9
- Citation Start Page
- 1452
- Citation End Page
- 1461
-
Appears in Collections:
- Medicine > Medicine
- Authorize & License
-
- Files in This Item:
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.